Elspar
FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors »
"The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to other FDA-approved t"...
Read the FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors article »
Elspar
PATIENT INFORMATION
Serious Allergic Reactions
Patients should be informed of the possibility of serious allergic reac-tions, including anaphylaxis, and advised to immediately report any swellings or difficulty breathing.
Thrombosis
Patients should be advised to immediately report any severe headache. Arm or leg swelling, acute shortness of breath, and chest pain also should be reported immediately.
Pancreatitis
Patients should be advised to immediately report any severe abdominal pain.
Glucose Intolerance
Patients should be advised to report excessive thirst or any increase in the volume or frequency of urination.
Last reviewed on RxList: 10/10/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Elspar Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Cancer
Get the latest treatment options.
Updated & New
